Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
aNK and ALT-803 in Stage III/IV Merkel Cell Carcinoma
NCT02465957Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Sep 2015
- Primary completion
- Mar 2018
- Countries
- 1
01
Overview
A Phase 2 trial of NK-92 in Merkel cell carcinoma (MCC), sponsored by ImmunityBio, Inc.. Started Sep 2015; status: terminated.
02
Drugs
NK-92
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT02465957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02465957.